Immunome Net Working Capital vs Total Stockholder Equity Analysis
| IMNM Stock | USD 9.82 0.40 4.25% |
Immunome financial indicator trend analysis is infinitely more than just investigating Immunome recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunome is a good investment. Please check the relationship between Immunome Net Working Capital and its Total Stockholder Equity accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.
Net Working Capital vs Total Stockholder Equity
Net Working Capital vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunome Net Working Capital account and Total Stockholder Equity. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Immunome's Net Working Capital and Total Stockholder Equity is 0.98. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Immunome, assuming nothing else is changed. The correlation between historical values of Immunome's Net Working Capital and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Immunome are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Net Working Capital i.e., Immunome's Net Working Capital and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.98 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Net Working Capital
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Immunome's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunome current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.At this time, Immunome's Selling General Administrative is very stable compared to the past year. As of the 24th of November 2024, Enterprise Value is likely to grow to about 121.1 M, while Issuance Of Capital Stock is likely to drop about 29.1 K.
| 2020 | 2023 | 2024 (projected) | Depreciation And Amortization | 755K | 728K | 736.1K | Interest Income | 1K | 2.7M | 2.9M |
Immunome fundamental ratios Correlations
Click cells to compare fundamentals
Immunome Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunome fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 5.1M | 44.5M | 57.9M | 24.0M | 148.5M | 156.0M | |
| Short Long Term Debt Total | 564K | 613K | 317K | 293K | 1.7M | 845.7K | |
| Other Current Liab | 666K | 1.4M | 6.3M | 4.7M | 7.7M | 3.9M | |
| Total Current Liabilities | 1.7M | 3.0M | 9.7M | 7.3M | 21.8M | 22.9M | |
| Total Stockholder Equity | (35.6M) | 41.3M | 48.2M | 16.7M | 119.9M | 125.9M | |
| Net Tangible Assets | (35.6M) | 41.3M | 48.2M | 16.7M | 19.2M | 10.0M | |
| Property Plant And Equipment Net | 1.7M | 1.5M | 855K | 965K | 3.6M | 2.0M | |
| Net Debt | (2.0M) | (39.2M) | (48.9M) | (20.0M) | (97.0M) | (92.2M) | |
| Retained Earnings | (36.6M) | (54.4M) | (79.1M) | (116.0M) | (222.8M) | (211.7M) | |
| Accounts Payable | 548K | 1.2M | 3.1M | 2.4M | 3.3M | 2.0M | |
| Cash | 2.5M | 39.8M | 49.2M | 20.3M | 98.7M | 103.6M | |
| Non Current Assets Total | 1.9M | 1.6M | 1.3M | 1.4M | 3.8M | 2.3M | |
| Cash And Short Term Investments | 2.5M | 39.8M | 49.2M | 20.3M | 138.1M | 145.0M | |
| Common Stock Shares Outstanding | 5.7M | 10.1M | 11.5M | 12.1M | 19.8M | 11.7M | |
| Liabilities And Stockholders Equity | 5.1M | 44.5M | 57.9M | 24.0M | 148.5M | 156.0M | |
| Non Current Liabilities Total | 39.0M | 142K | 12K | 62K | 6.8M | 9.9M | |
| Capital Lease Obligations | 239K | 0.0 | 317K | 293K | 1.7M | 1.7M | |
| Other Current Assets | 579K | 5.4M | 2.6M | 2.9M | 6.3M | 3.4M | |
| Other Stockholder Equity | 927K | 95.7M | 69.4M | 132.7M | 342.7M | 359.8M | |
| Total Liab | 40.7M | 3.2M | 9.7M | 7.4M | 28.7M | 15.9M | |
| Net Invested Capital | (35.3M) | 42.0M | 48.2M | 16.7M | 119.9M | 125.9M | |
| Property Plant And Equipment Gross | 1.7M | 1.5M | 3.9M | 681K | 7.5M | 7.9M | |
| Total Current Assets | 3.1M | 42.9M | 56.6M | 22.6M | 144.7M | 151.9M | |
| Accumulated Other Comprehensive Income | (38.9M) | (44.5M) | (57.9M) | 0.0 | 22K | 23.1K | |
| Net Working Capital | 1.5M | 39.9M | 46.9M | 15.3M | 122.9M | 129.0M | |
| Short Term Debt | 451K | 479K | 317K | 229K | 310K | 319.7K | |
| Property Plant Equipment | 1.7M | 1.5M | 855K | 681K | 612.9K | 1.1M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.